Chen Xian, Lun Limin, Hou Huabin, Tian Runhua, Zhang Haiping, Zhang Yunyuan
Cell Physiol Biochem. 2017;41(4):1424-1434. doi: 10.1159/000468005. Epub 2017 Mar 17.
Growing evidence from recent studies has shown that lncRNA HULC plays a role in the development of multiple carcinomas. This meta-analysis aimed to analyze available data to identify the prognostic value of HULC in multiple tumors.
A systematic search was performed by using PubMed (medline), Embase, ISI Web of Knowledge, Springer, the Cochrane Library, Scopus, BioMed Central, ScienceDirect, Wanfang, Weipu, and China National Knowledge Internet (CNKI) computerized databases from inception to Nov 30, 2016. The quality of the publications was assessed according to the critical review checklist of the Dutch Cochrane Centre proposed by MOOSE and PRISMA. Pooled hazard ratios (HR) with 95% confidence interval (95% CI) were calculated to summarize the effect.
A total of ten studies with 1077 cancer patients were pooled in the present meta-analysis to evaluate the prognostic value of HULC in multiple tumors. High expression levels of HULC were demonstrated to be associated with poor overall survival (OS) (HR=2.44, 95%CI: 1.96-3.03, P=0.000). Subgroup analysis showed that cancer type (digestive or non-digestive disease), residence region (China), sample size (more or less than 100) and follow-up months (more or less than 60) did not alter the predictive value of HULC on OS in various cancers. Additionally, increased HULC expression was found to be moderately associated with tumor stage and progression (III/IV vs. I/II: HR=1.59, 95% CI: 1.31-1.92, P<0.00001). Furthermore, elevated HULC expression significantly predicted distant metastasis (HR=3.90, 95% CI: 1.89-8.02, P=0.0002) and lymph node metastasis (HR=2.04, 95% CI: 1.03-4.05, P=0.04) respectively. No significant heterogeneity was observed among studies except lymph node metastasis.
The results indicate that HULC expression level is an independent prognostic biomarker for unfavorable OS and metastasis in general tumors.
近期研究的越来越多证据表明，长链非编码RNA HULC在多种癌症的发展中起作用。本荟萃分析旨在分析现有数据，以确定HULC在多种肿瘤中的预后价值。
通过使用PubMed（医学文献数据库）、Embase、ISI Web of Knowledge、Springer、Cochrane图书馆、Scopus、BioMed Central、ScienceDirect、万方、维普和中国知网（CNKI）计算机数据库，从数据库建立至2016年11月30日进行系统检索。根据MOOSE和PRISMA提出的荷兰Cochrane中心的关键评价清单评估出版物的质量。计算合并风险比（HR）及95%置信区间（95%CI）以总结效应。
本荟萃分析共纳入10项研究中的1077例癌症患者，以评估HULC在多种肿瘤中的预后价值。结果表明，HULC高表达与总体生存期（OS）较差相关（HR=2.44，95%CI：1.96-3.03，P=0.000）。亚组分析显示，癌症类型（消化或非消化系统疾病）、居住地区（中国）、样本量（大于或小于100）和随访月数（大于或小于60）均未改变HULC对各种癌症OS的预测价值。此外，发现HULC表达增加与肿瘤分期和进展中度相关（III/IV期与I/II期：HR=1.59，95%CI：1.31-1.92，P<0.00001）。此外，HULC表达升高分别显著预测远处转移（HR=3.90，95%CI：1.89-8.02，P=0.0002）和淋巴结转移（HR=2.04，95%CI：1.03-4.05，P=0.04）。除淋巴结转移外，各研究间未观察到显著异质性。
结果表明，HULC表达水平是一般肿瘤中OS不良和转移的独立预后生物标志物。
